Monobenzone

• CAT Number: A000728
• CAS Number: 103-16-2
• Molecular Formula: C13H12O2
• Molecular Weight: 200.23
• Purity: ≥95%
• Target: Tyrosinase Inhibitor
• Storage: -20°C
• IUPAC Name: 4-phenylmethoxyphenol
• InChI: InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2
• InChIKey: VYQNWZOUAUKGHI-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)COC2=CC=C(C=C2)O

Monobenzone(CAT: A000728) is a chemical compound primarily associated with the field of cosmetics and dermatology. Its action method involves depigmentation of the skin by inhibiting melanin production. Monobenzone is used topically as a skin-lightening agent, particularly in the treatment of conditions like vitiligo, where there is a loss of skin pigmentation.

Reference

1: Arowojolu OA, Orlow SJ, Elbuluk N, Manga P. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp Dermatol. 2017 Jul;26(7):637-644. doi: 10.1111/exd.13350. PubMed PMID: 28370349; PubMed Central PMCID: PMC5507766.
2: Lee CS, Joo YH, Baek HS, Park M, Kim JH, Shin HJ, Park NH, Lee JH, Park YH, Shin SS, Lee HK. Different effects of five depigmentary compounds, rhododendrol, raspberry ketone, monobenzone, rucinol and AP736 on melanogenesis and viability of human epidermal melanocytes. Exp Dermatol. 2016 Jan;25(1):44-9. doi: 10.1111/exd.12871. Epub 2015 Nov 23. PubMed PMID: 26440747.
3: Zhu Y, Wang S, Xu A. A mouse model of vitiligo induced by monobenzone. Exp Dermatol. 2013 Jul;22(7):499-501. doi: 10.1111/exd.12184. PubMed PMID: 23800067.
4: Rordam OM, Lenouvel EW, Maalo M. Successful treatment of extensive vitiligo with monobenzone. J Clin Aesthet Dermatol. 2012 Dec;5(12):36-9. PubMed PMID: 23277803; PubMed Central PMCID: PMC3533321.
5: van den Boorn JG, Melief CJ, Luiten RM. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 2011 Aug;24(4):673-9. doi: 10.1111/j.1755-148X.2011.00878.x. Epub 2011 Jul 6. Review. PubMed PMID: 21689385.
6: van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, van Capel T, Jong EC, Reits EA, Drijfhout JW, Bos JD, Melief CJ, Luiten RM. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011 Jun;131(6):1240-51. doi: 10.1038/jid.2011.16. Epub 2011 Feb 17. PubMed PMID: 21326294.
7: van den Boorn JG, Konijnenberg D, Tjin EP, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JP, Bos JD, Melief CJ, Luiten RM. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One. 2010 May 13;5(5):e10626. doi: 10.1371/journal.pone.0010626. PubMed PMID: 20498710; PubMed Central PMCID: PMC2869359.
8: Manini P, Napolitano A, Westerhof W, Riley PA, d/'Ischia M. A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity. Chem Res Toxicol. 2009 Aug;22(8):1398-405. doi: 10.1021/tx900018q. PubMed PMID: 19610592.
9: Catona A, Lanzer D. Monobenzone, Superfade, vitiligo and confetti-like depigmentation. Med J Aust. 1987 Mar 16;146(6):320-1. PubMed PMID: 3821640.
10: Nordlund JJ, Forget B, Kirkwood J, Lerner AB. Dermatitis produced by applications of monobenzone in patients with active vitiligo. Arch Dermatol. 1985 Sep;121(9):1141-4. PubMed PMID: 2931053.